Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
56.82 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Crinetics Pharmaceuticals, Inc. |
Symbool | CRNX |
Munteenheid | USD |
Prijs | 56.82 |
Beurswaarde | 5,115,822,792 |
Dividendpercentage | 0% |
52-weken bereik | 25.75 - 60.04 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. R. Scott Struthers Ph.D. |
Website | https://www.crinetics.com |
An error occurred while fetching data.
Over Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)